Veradermics MANE Business Segments — Net loss
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Veradermics in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The official record: Veradermics ’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Veradermics 's business segments — net loss.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Veradermics 's business segments — net loss?
- Veradermics (MANE) reported business segments — net loss of -$27.23M in Q1 2026.
- How has Veradermics 's business segments — net loss changed year-over-year?
- Veradermics 's business segments — net loss decreased by 119.6% year-over-year, from -$12.4M to -$27.23M.
- What does business segments — net loss mean?
- This metric represents the net financial loss generated by the company's operations after accounting for all revenues and expenses. As a pre-revenue or early-stage biopharmaceutical company, this figure highlights the current burn rate required to sustain development activities. It is the primary indicator of the company's financial health and capital consumption.